期刊文献+

男性青少年性腺功能减退症患者短期雄激素替代治疗对血脂和hsCRP水平的影响 被引量:2

The effect of androgen replacement therapy in hypogonadal young male patients on serum lipid profile and hsCRP level
暂未订购
导出
摘要 目的探讨性腺功能低减的青少年男性,短期雄激素替代治疗对血脂和超敏C反应蛋白(hsCRP)的影响。方法本研究为前瞻性自身对照研究,共纳入33例性腺功能减退青少年男性。行短期(9个月)雄激素替代治疗,比较治疗前后血睾酮水平、第二性征发育程度、身高、握力、血红蛋白、血脂和hsCRP的差异。结果(1)替代治疗后,睾酮水平明显升高,第二性征明显发育,身高、握力、血红蛋白显著增加(P值均<0.05);(2)短期雄激素替代治疗后,总胆固醇(TC),低密度脂蛋白(LDL-c),高密度脂蛋白(HDL-c)和甘油三酯(TG)都有所下降,但无统计学差异(P>0.5)。超敏CRP显著下降(P=0.025)。结论(1)性腺功能低减的青少年男性,短期雄激素替代治疗,可以促进第二性征发育,增加身高、握力和血红蛋白;(2)短期雄激素替代治疗,对血脂无显著性影响。但是,可以使hsCRP明显下降。 Objective To investigate the effect of short period of androgen replacement therapy in hypogonadal young male patients on serum lipid profile and high sensitive C-reactive protein (hsCRP) level. Methods It was a prospective and self-comparison designed study which recruited in 33 hypogonadal young male patients, The parameters of serum testosterone, penile growth, height, hand wrest strength, hemoglobin, lipid profile and hsCRP before and after androgen replacement treatment were compared. Results (1) The serum testosterone, penile growth, height, hand wrest strength, and hemoglobin were increased after androgen replacement (P〈0.05). (2) The level of total cholesterol, LDL-c, HDL-c and triglyceride were all decreased but with no significance (P〉0.05). The level of hsCRP was significantly reduced (P=0.025). Condusion (1) Short period of androgen replacement therapy in hypogonadal young male patients could increase the penile growth, height, hand wrest strength and hemoglobin. (2) Such androgen replacement therapy had no significant effect on lipid profile, but could significant reduce the level of hsCRP.
出处 《中国男科学杂志》 CAS CSCD 2007年第2期31-33,共3页 Chinese Journal of Andrology
关键词 性腺功能低减 雄激素 血脂 超敏C反应蛋白 hypogonadism androgen lipid hsCRP
  • 相关文献

参考文献10

  • 1Kupelian V, Page ST, Araujo AB, et al. Low sex hormonebinding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91(3): 843-850. Epub 2006 Jan 4
  • 2Demirbag R, Yilmaz R, Ulucay A, et al. The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocr Res 2005; 31 (4): 335-344
  • 3Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol 2006; 106(3): 291-297
  • 4Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003; 24(3): 313-340
  • 5Whitsel EA, Boyko EJ, Matsumoto AM, et al. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111 (4): 261-269
  • 6Gordon D J, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79(1):8-15
  • 7Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998; 81(4A): 26B-31B
  • 8Jukema JW, Liem AH, Dunselman PH, et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) Study. Curr Med Res Opin 2005; 21(11):1865-1874
  • 9Memon L, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N,et al. Association of C-reactive protein with the presence and extent of angiographically verified coronary artery disease. Tohoku J Experi Med 2006; 209 (3): 197-206
  • 10Pfutzner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006; 8(1): 28-36

同被引文献31

  • 1刘杰.雄激素替代疗法的现在和将来[J].国外医学(药学分册),2005,32(4):259-261. 被引量:4
  • 2Hughes IA, Hank C, Ahmed SF, et al. Consensus statement on management of intersex disorders. Arch Dis Child, 2006, 91 (7) : 554-563.
  • 3Wiesemann C, Ude-Koeller S, Sinnecker GH, et al. Ethical principles and recommendations for the medical management of differences of sex development (DSD)/intersex in children and adolescents. Eur J Pediatr, 2010, 169(6) :671-679.
  • 4Nelson CP, Park JM, Wan J, et al. The increasing incidence of congenital penile anomalies in the United States. J Urol, 2005, 174(4 Pt 2) :1573-1576.
  • 5Ishii T, Sasaki G, Hasegawa T, et al. Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis. J Urol, 2004, 172 (1) : 319-324.
  • 6Sharma S, Gupta DK. Gender assignment and hormonal treatment for disorders of sexual differentiation. Pediatr Surg Int, 2008, 24(10) :1131-1135.
  • 7Butler GE, Sellar RE, Walker RF, et al. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmaeokineties and effects on sexual maturation and growth. J Clin Endocrinol Metab, 1992, 75 ( 1 ) :37-44.
  • 8Kshn FM, Schill WB. A new oral testosterone undecanoate ormulation. World J Urol, 2003, 21 (5) :311-315.
  • 9Feldman KW, Smith DW. Fetal phallic growth and penile standards for newborn male infants. J Pediatr, 1975, 86(3 ) : 395-398.
  • 10Calikoglu AS. Should boys with micropenis be reared as girls? J Pediatr, 1999, 134(5) :537-538.

引证文献2

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部